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| INTRODUC TI ON
Epidermal growth factor receptor (EGFR) is an established therapeutic target in various solid malignancies including squamous cell carcinoma of the head and neck (SCCHN) and colon carcinoma. 1, 2 Cetuximab, an immunoglobulin G1 chimeric human/murine monoclonal antibody, specifically binds to the EGFR with high affinity. The proposed mechanisms of its anticancer activity include inhibition of receptor activation by natural ligands, endocytosis of the receptor and activation of antibody-dependent cell-mediated cytotoxicity through the activation of macrophages and natural killer cells. 3 Cetuximab has been evaluated in the treatment of recurrent or metastatic SCCHN as monotherapy and in combination with platinum-containing regimen. [4] [5] [6] The addition of cetuximab to platinum-containing regimen has shown a significant increase in response rate. Currently, cetuximab in combination with cisplatin or carboplatin plus 5-fluorouracil (5-FU) is an accepted standard of care in first-line recurrent/metastatic SCCHN. [7] [8] [9] [10] [11] We evaluated the pharmacokinetics and potential drug-drug interactions between cetuximab and cisplatin or carboplatin. Here we report results from two phase II pharmacokinetic studies, one evaluated pharmacokinetics of cetuximab and cisplatin (JXBA study), and the second evaluated pharmacokinetics of cetuximab and carboplatin (JXBB study). The studies were conducted in response to a postmarketing request by the US Food and Drug Administration to further characterize the pharmacokinetics of cetuximab with cisplatin/carboplatin when these two agents were coadministered and to investigate any potential for drug-drug interactions. The main rationale for this request was that the US Food and Drug Administration determined that the analysis of spontaneous post-marketing adverse events (AEs) reported was not sufficient to evaluate the known serious risks of infusion reactions, cardiopulmonary arrest, pulmonary toxicity and dermatologic toxicity caused by drug exposures when administered at recommended dose and schedule. Few AEs were also reported to adequately identify unexpected serious risks from drug-drug interactions between cetuximab and cisplatin or cetuximab and carboplatin.
The JXBA and JXBB studies were conducted to address these issues.
| ME THODS

| Study design
JXBA (NCT01099358) and JXBB (NCT01063075) studies were multicenter, open-label phase II trials designed to evaluate the drug-drug interactions between cetuximab and cisplatin (JXBA) or carboplatin (JXBB) with or without 5-FU in patients with advanced solid tumors.
The JXBA study was conducted at six centers in the USA and Canada whereas the JXBB study was conducted at seven centers in these two countries. Institutional review boards at all participating institutions approved the study protocol(s). All patients gave written informed consent. These studies were conducted according to good clinical practice, and the Declaration of Helsinki and its amendments.
Both studies were amended to address ongoing patient recruitment and retention challenges, including providing investigators the flexibility to enroll patients with any advanced solid tumor histology.
In the original randomized, two-arm design the effect of cetuximab on the pharmacokinetic parameters of cisplatin or carboplatin was studied in one arm (group A), while the effect of cisplatin or carboplatin on the pharmacokinetic parameters of cetuximab was investigated in the other arm (group B). This design had ongoing patient recruitment and retention challenges and was therefore discontinued. Instead, a single-arm study design was introduced and patients were enrolled in group C. In both JXBA and JXBB studies, patients in group C received up to six cycles of combination therapy. Thereafter, treatment with cetuximab monotherapy was permitted until there was evidence of progressive disease, unacceptable toxicity or another withdrawal criterion was met. Due to challenges, patient enrollment in group C was discontinued and enrollment in group D was initiated. Patients in group D, received one cycle of cetuximab in combination with cisplatin with or without 5-FU (JXBA study), or one cycle of cetuximab in combination with carboplatin with or without 5-FU (JXBB study).
The treatment schedule was designed to investigate the influence of cetuximab on the single-dose pharmacokinetics of the platinum compounds. In both the studies, the main inclusion criteria were that patients (male and female) should be 18 years or older with histologically or cytologically confirmed advanced solid tumors and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
| Study objectives
The primary objectives of the studies were to investigate the pharmacokinetics of cetuximab in combination with cisplatin (JXBA) or carboplatin (JXBB) in patients with advanced solid tumors and to assess the potential for drug-drug interactions. The secondary objective was to assess the safety of cetuximab in combination with cisplatin or carboplatin, with or without 5-FU.
| Dosage
For group C, the duration of cycle 1 was for 4 weeks and of cycles 2-6 was for 3 weeks. Cisplatin (100 mg m −2 ) or carboplatin area under the curve (AUC) 5 mg × min mL −1 was administered over and to assess the potential for drug-drug interactions between cetuximab and cisplatin. On day 1 of cycle 1, group D patients received an intravenous infusion of cetuximab (400 mg m −2 initial dose) followed by cisplatin (100 mg m −2 ) or carboplatin AUC 5 mg × min mL −2 . The 5-FU (1000 mg m −2 d −1 ) was an optional treatment administered on day 1 through day 4. Infusion durations for all drugs were the same as noted for Group C above. Patients in group D who completed one cycle of combination chemotherapy were permitted continued access to cetuximab in the absence of progression, unacceptable toxicity or until another withdrawal criterion.
| Bioanalytical methods
Concentrations of cetuximab, cisplatin and carboplatin were determined using validated analytical methods. In both the studies, the serum samples obtained were analyzed for cetuximab using a validated enzyme-linked immunosorbent assay at ICON Laboratory Services, Inc (Whitesboro, NY, USA). The lower limit of quantification was 0.100 µg mL −1 and the upper limit of quantification was 6.400 µg mL −1 . Samples above the limit of quantification were diluted to yield results within the calibrated range. Plasma samples obtained during both studies were analyzed for total and free platinum using a validated inductively coupled mass spectrometry method at Maxxam Analytics International Corporation (Burnaby, British Columbia, Canada). Free platinum was determined in protein-precipitated human plasma. The lower limit of quantification for both free and total platinum was 0.050 µg mL −1 and the upper limit of quantification was 2.000 µg mL −1 . Samples above the limit of quantification were diluted to yield results within the calibrated range.
| Pharmacokinetic analyses
In both studies, pharmacokinetic analyses were conducted for those patients who received the study drug and had evaluable concentration data suitable for noncompartmental analysis. Blood for the pharmacokinetic analyses was drawn on day 1 of cycle 1 immediately prior to cisplatin/carboplatin infusion and then 1, 1.5, 2, 3, 5, 8, 24, and 72 hours after the start of the cisplatin infusion. Pharmacokinetic parameters estimates were calculated using Phoenix WinNonlin 6.4. The AUC for cetuximab and total cisplatin or carboplatin was calculated by a combination of the linear and logarithmic trapezoidal methods.
| Safety
All patients who received any quantity of study drug were evaluated for safety and toxicity. The safety and tolerability of cetuximab was determined by reported AEs, physical examinations, vital signs and laboratory assessments. Table 1 summarizes patient demographics and baseline characteristics of patients included in both the studies. In the JXBA study, 44 patients were treated; of which, 56.8% (n = 25) were men and 43.2% (n = 19) were women. Over half of the patients (68.2%) had a baseline ECOG performance status score of 1. In the JXBB study, 34 patients were treated; of which, 76.5% (n = 26) were men and 23.5% (n = 8) were women; 67.6% of patients had a baseline ECOG performance status score of 1.
| RE SULTS
| Patient characteristics
| Pharmacokinetic evaluation
In the study JXBA, cetuximab pharmacokinetic parameters were compared when cetuximab was administered alone and in combination with cisplatin. There were 14 patients with cetuximab were similar when cetuximab was administered alone or in combination with cisplatin ( Figure 1A ). The C max , t max and overall AUC for the cetuximab group (194 µg mL −1 , 2.0 h, 14 900 µg × h mL −1 ) and The effect of cetuximab on cisplatin pharmacokinetics was evaluated when cisplatin was administered alone or in combination with cetuximab. Cisplatin analysis was based on total cisplatin concentration (both unbound and bound platinum) and data showed that mean total cisplatin concentrations were similar when cisplatin was administered with or without cetuximab (Figure1B). The C max , t max and overall AUC for the cisplatin group (4.08 µg mL −1 , 1.02 h, 132 µg × h mL −1 ) and the cisplatin and cetuximab combination group (4.22 µg mL −1 , 1.05 h, 126 µg × h mL −1 ) were similar. Table 2 shows the geometric means, their ratios, and 90% CIs for The effect of cetuximab on carboplatin pharmacokinetics was evaluated when carboplatin was administered with and without coadministration of cetuximab. Carboplatin analysis was based on total platinum (both the unbound and bound in plasma). Data showed that there was no clinically relevant change in total carboplatin exposures when carboplatin was coadministered with cetuximab ( Figure 2B ).
The C max and t max for the carboplatin group was 16.9 µg mL −1 , 1.04 h, respectively and for the carboplatin and cetuximab combination group was 11.9 µg mL −1 , 1.07 h, respectively. The 90% CIs for AUC (0-72) and AUC (0-tlast) were within the boundary of 0.909-1.21 and the ratios of AUC (0-72) and AUC (0-tlast) were within the percentage Table 3 shows the cetuximab pharmacokinetic parameters estimates from both JXBA and JXBB studies. These parameters further demonstrate that the C max , t max and overall exposure to cetuximab were similar between the two treatments.
| SAFE T Y
In the JXBA study, 95.5% (n = 42) of patients discontinued the study. (Table 4 ).
There was no death during the study duration but three patients died within 30 days of the last dose of study drug (one patient from group B and two patients from group C).
A total of 34 (100.0%) patients discontinued the JXBB study. The reasons for discontinuation were AE (8.8%), progressive disease per RECIST (55.9%), progressive disease (symptomatic deterioration; 14.7%), withdrawal of consent with further follow-up (5.9%) and without further follow-up (2.9%) and other (11.8%; other reasons included patient wished to discontinue therapy, patient was noncompliant with study protocol rules, principal investigator chose to stop treatment as he felt there were no further benefits to be had by continuing study treatment and patient completed study therapy).
In the JXBB study, 50.0% (n = 17) of patients experienced at least one SAE and 2.9% (n = 1) patient had an SAE related to cetuximab. The cetuximab-related SAE was grade 3 pneumonia. All patients experienced at least one AE/TEAE; 91.2% (n = 31) of patients experienced at least one cetuximab-related AE. In all, 52.9% (n = 18) of patients had AEs/TEAEs that resulted in a dose delay/modification (Table 4 ). There was no death during the study duration but three patients (all from group D) died within 30 days of the last dose of study drug.
| D ISCUSS I ON
These studies (JXBA and JXBB) were conducted to further characterize the pharmacokinetics of cetuximab and cisplatin (JXBA) or carboplatin (JXBB) when the two agents were coadministered and to investigate the potential for drug-drug interactions. In both the studies, two-way drug interaction was investigated.
In the JXBA study, cetuximab pharmacokinetics parameters In the JXBB study, data showed that the mean AUC (0-72) and To conclude, in the JXBA and JXBB studies, no evidence of drugdrug interaction between cetuximab and either cisplatin or carboplatin was observed. No new safety signals were observed in either study. These findings provide further evidence that cetuximab can safely be given in combination with cisplatin or carboplatin, allowing clinicians to more confidently administer such regimens to patients who could potentially benefit.
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